# Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo

> **NCT02092389** · — · TERMINATED · sponsor: **AbbVie** · enrollment: 10 (actual)

## Conditions studied

- Moderate to Severe Ulcerative Colitis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02092389
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2014-07
- **Primary completion:** 2015-10
- **Final completion:** 2016-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Recruitment below expectation
- **Last updated:** 2017-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02092389

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02092389, "Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02092389. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*